Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Sclerostin tied to lower skeletal mass in healthy people

27 Oct 2019

Serum levels of sclerostin are independently but inversely correlated with skeletal mass in healthy individuals, a new study has found.

Researchers performed a cross-sectional analysis on 240 healthy, nondiabetic individuals whose body composition was measured using dual-energy X-ray absorptiometry. Low muscle mass was defined as <7.0 kg/m2 in males and <5.4 kg/m2 in females. Serum sclerostin was measured from overnight fasting blood samples using enzyme-linked immunosorbent assays.

Grouping participants into tertiles of skeletal mass index, researchers found that serum sclerostin levels peaked in the bottom tertile and decreased linearly with increasing skeletal mass.

Adjusting for sex, age, body mass index (BMI), smoking status, alcohol consumption and regular exercise, among other variables, did not attenuate this relationship. The overall prevalence rate of low muscle mass was only 11.2 percent.

Serum sclerostin was also significantly and inversely correlated with fasting plasma glucose (FPG) and the ratio between appendicular skeletal muscle mass and the square of height (p<0.001 for both). Direct and significant associations were observed for percent total body fat and bone mineral content (BMC; p<0.001 for both).

“The study shows that osteocyte-derived sclerostin had a significant association with skeletal muscle mass,” said researchers. “Importantly, sclerostin had negative effects on skeletal muscle mass independent of age, sex, BMI, lifestyle parameters, FPG, BMC and total body fat mass.”

Future studies should consider better measurement methods for sclerostin, such as mass spectrometry, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.